ESMA Prospectus Disclosure Guidelines: The 9 November 2026 Deadline

ESMA published a full package of prospectus materials on 9 September 2026, and only one part of it is still open for comment. The European Securities and Markets Authority put out a Consultation Paper on updated Guidelines on disclosure requirements under the Prospectus Regulation (Regulation (EU) 2017/1129), revised its Q&As, finalised Guidelines on supplements that introduce new securities to a base prospectus, and published a Final Report on proposed updates to the regulatory technical standards on key financial information in a prospectus summary. Issuers, arrangers and their legal advisers have until 9 November 2026 to respond to the consultation on the prospectus disclosure Guidelines.

The package exists to catch the rulebook up with the Listing Act (Regulation (EU) 2024/2809), whose core prospectus changes apply from 5 June 2026, and to strip out guidance that no longer serves any purpose. ESMA has said it expects to publish the Final Report and the updated Guidelines in Q2 2027. That leaves a working window this autumn in which the drafting choices that will shape prospectus disclosure for the next several years are still movable.

The practical task for anyone who drafts or reviews prospectuses is narrower than the four-part package suggests. One item is a live consultation. The other three are further along, and each carries a different status and a different date. Getting that sorted first is what tells you where your comment letter can still make a difference and where the drafting is already fixed.

Related reading: our guide to the European Single Access Point (ESAP), the platform that will host prospectuses and regulated disclosure across the EU.

The dates that drive this package

Deadline pressure is the reason this topic matters now, so the calendar comes first.

• 4 December 2024 is when the Listing Act (Regulation (EU) 2024/2809) entered into force, opening the staggered application of its prospectus amendments.
• 5 June 2026 is the date from which the core Listing Act changes to the Prospectus Regulation apply, including the move to a standardised sequence and format for prospectuses.
• 9 September 2026 is the day ESMA published the package: the Consultation Paper, the revised Q&As, and two Final Reports.
• 9 November 2026 is the deadline to respond to the consultation on the updated disclosure Guidelines.
• Q2 2027 is when ESMA expects to publish the Final Report and the updated Guidelines.
• The Guidelines on product supplements will apply when the translations into all official EU languages become available, as confirmed by ESMA’s press release on the Final Report; the exact trigger wording should be checked against ESMA Final Report ESMA32-753890202-3034.
• ESMA published a Final Report on the update to the summary RTS on 9 September 2026; Commission adoption of the amended RTS would be required before those changes become applicable law.

The 9 September package: prospectus disclosure after the Listing Act

ESMA describes the release as a package under the Prospectus Regulation that reflects the changes introduced by the Listing Act and supports its simplification and burden-reduction work. It also frames the measures as promoting supervisory convergence, so that the same disclosure is read the same way by regulators in different Member States. Four items sit inside it.

The first is a Consultation Paper (reference ESMA32-753890202-3085) on the update to the Guidelines on disclosure requirements. The second is a set of revised Q&As, accompanied by an overview that explains the key changes and the reasons behind them. The third is a Final Report on Guidelines for supplements that introduce new securities to a base prospectus, the so-called product supplements (reference ESMA32-753890202-3034). The fourth is a Final Report on updated regulatory technical standards on the key financial information in a prospectus summary (reference ESMA32-753890202-3065).

The operational point that gets missed on a first read is that the 9 November 2026 deadline attaches to the consultation alone. The Q&As are already revised and published. The two Final Reports represent completed ESMA work, with the supplements Guidelines awaiting translation and the summary RTS awaiting a Commission decision. A comment letter aimed at the product-supplement test or the summary tables has no live consultation to land in; the moment to influence those has passed. Treat the four items as four separate tracks before you allocate any review time.

What the disclosure Guidelines actually govern

The Guidelines on disclosure requirements address disclosure items in Commission Delegated Regulation (EU) 2019/980, as amended by Commission Delegated Regulation (EU) 2026/1061, which now sets the detailed format, sequence, content, scrutiny and approval framework for prospectuses. The annexes list what a registration document and a securities note must contain for each type of issuer and security. The Guidelines explain how ESMA and national competent authorities expect particular annex items to be completed, which is why they matter as much to the person completing the document as to the lawyer reading the regulation. When a national competent authority scrutinises a draft prospectus, it tests the disclosure for completeness, comprehensibility and consistency before approval. The Guidelines shape that judgement, so a change in guidance can move where a reviewer pushes back even when the annex text itself is untouched.

These Guidelines are issued under Article 16 of the ESMA Regulation (Regulation (EU) No 1095/2010), which means they operate on a comply-or-explain basis. Once finalised, each national competent authority tells ESMA whether it complies, intends to comply, or explains why not. That status has a consequence worth stating plainly: the updated Guidelines will not add disclosure line-items that are absent from the annexes of 2019/980. They interpret and steer the application of requirements that already exist in Level 1 and Level 2 text. Reading them as a fresh checklist of new fields overstates what a guideline can do.

Reading the consultation against your prospectus disclosure templates

ESMA frames the update as helping issuers and advisers understand the disclosure expected under the revised Prospectus Regulation, while also simplifying the existing guidance by removing parts that are no longer necessary. Both halves of that sentence create review work, and the second half is easy to underrate.

Where drafting teams get this wrong is by scanning only for new expectations and skipping the deletions. When guidance is withdrawn, a prospectus that still follows the old wording is not automatically wrong, but the rationale for a disclosure choice may no longer point anywhere. A short diff exercise answers the question that matters at scrutiny: for each place your house template cites or leans on the current Guidelines, is that guidance retained, reworded, or gone. A deleted Guideline should trigger a re-check of the governing Level 1 and Level 2 requirements; deletion of Level 3 guidance does not by itself establish that an NCA will no longer expect the underlying disclosure or that the prospectus can be shortened. That reading also feeds the standardised-format work, because a leaner sequence only helps if the underlying disclosure has been trimmed to match. ESMA’s related work on issuer reporting, such as ESMA’s guidelines on alternative performance measures, shows how closely summary financial presentation and narrative disclosure interact.

The Q&As: realigned references, not a change in the law

The revised Q&As do three things, on ESMA’s own account: they adjust legal references to reflect the amended Prospectus Regulation, add clarifications where they were needed, and remove obsolete content. ESMA has also prepared an overview that walks through the key changes and the reasons for them.

A Q&A is a supervisory convergence tool. It records how ESMA reads a provision so that national authorities apply it consistently; it does not create or amend an obligation. The most useful way to handle this update is to treat the overview as a change-log. Run it against the internal notes and precedents your team relies on, and retire any position that quotes a Q&A ESMA has now deleted or rewritten. Legal references changed because the Listing Act amended, replaced, deleted or inserted Prospectus Regulation provisions and cross-references, so an internal citation that was correct before the amendments may now point to a superseded provision.

Product supplements: the new-securities test for base prospectuses

The Final Report on product supplements (ESMA32-753890202-3034) sets out a common approach for deciding whether a supplement introduces new securities to a base prospectus. ESMA’s stated aim is to give national competent authorities a methodological, easy-to-apply framework and to give market participants more certainty when they submit supplements.

The distinction is operational for any programme issuer. A supplement is the mechanism for updating a base prospectus during its validity, for example to add a significant new factor or correct a material mistake. Article 23(4a) provides that a supplement to a base prospectus must not be used to introduce a new type of security for which the necessary information was not included in the base prospectus, unless doing so is necessary to comply with capital requirements under Union law or national law transposing Union law. The Guidelines are meant to make that boundary predictable, so that an arranger is not guessing whether the regulator will accept a supplement or send the issuer back to prepare fresh documentation. The line tends to blur where a programme adds a materially different security type, and the Guidelines are aimed squarely at that grey zone. The Guidelines will apply when the translations into all official EU languages become available, per ESMA’s press release on the Final Report; confirm the exact trigger in ESMA32-753890202-3034 before implementation. Programme issuers with drawdowns planned for 2027 should track the translation status before assuming immediate effect.

Summary key financial information: the RTS update to 2019/979

The fourth item is a Final Report on updated regulatory technical standards for the key financial information to be included in a prospectus summary (ESMA32-753890202-3065). It updates Commission Delegated Regulation (EU) 2019/979, the standard that already governs the key financial information in the summary, the publication and classification of prospectuses, advertisements, supplements and the notification portal. ESMA published its Final Report on the update to the RTS concerning key financial information in the summary of a prospectus on 9 September 2026; Commission adoption of amended RTS would be required before those amendments become applicable law.

The prospectus summary is subject to specific requirements for key financial information, including prescribed tables under Commission Delegated Regulation (EU) 2019/979. ESMA has published a Final Report on updating the RTS concerning key financial information in the summary of a prospectus. The status point is the one to carry into any planning: this is a submitted draft, not adopted law. Until the Commission adopts the updated RTS and it enters into force, the existing 2019/979 tables continue to apply. Anyone building summary templates now should design for the current standard while flagging the pending change, because the summary sits under a length cap and the table structure is what fills it.

Why ESMA is moving now

The timing follows the Listing Act. Regulation (EU) 2024/2809 amended the Prospectus Regulation, the Market Abuse Regulation and MiFIR, and its prospectus changes apply on a staggered basis between December 2024 and June 2026. From 5 June 2026, the Level 1 standardised-format and sequence requirement applies, and Article 3(2) exempts an offer only where it is not subject to Article 25 notification and the total aggregated consideration in the Union is less than EUR 12 million per issuer or offeror over 12 months; under Article 3(2a), a Member State may instead apply a less-than-EUR 5 million threshold. The Listing Act provides an admission-to-trading exemption for securities fungible with securities already admitted on the same regulated market where they represent, over 12 months, less than 30% of the number already admitted; separate offer-to-the-public exemptions for fungible securities are subject to additional conditions. Level 2 and Level 3 material then has to be reconciled with that new Level 1 text, which is what this package does.

The simplification framing carries weight. ESMA has tied the release to its burden-reduction agenda, and the same current runs through adjacent files such as the CSRD simplification package and the build-out of centralised disclosure infrastructure. For issuers that also raise under labelled regimes, the interaction with the EU Green Bond issuer-reporting regime is worth keeping in view, since a single transaction can trigger more than one disclosure track. What ESMA has not done is compress the timetable: the disclosure Guidelines will not be final until Q2 2027, well after the Level 1 changes apply, so drafting through late 2026 runs against amended primary text while the interpretive layer is still in draft.

What to review before 9 November 2026

The consultation is the only part of the package where a response changes the outcome, so the pre-deadline work is focused. Read the Consultation Paper (ESMA32-753890202-3085) alongside the overview of the Q&A changes, because the two together show how ESMA now reads the amended framework. Map your current prospectus and base-prospectus templates against the draft guidance, marking both the new expectations and the withdrawn guidance. Pull in debt capital markets, equity capital markets and external counsel early, since disclosure choices that look like drafting preferences often reflect a firm-wide position that a comment letter would commit to.

Responses go to ESMA through the consultation response mechanism on its website before 9 November 2026. A letter that identifies a specific annex item where the draft guidance is unclear, or where a deletion removes a treatment your issuers rely on, is worth more than a general endorsement. After the window closes, the drafting passes to ESMA for the subsequent Final Report.

Frequently Asked Questions

Does the 9 November 2026 deadline apply to all four items in the package?

No. It applies only to the Consultation Paper on the updated disclosure Guidelines (ESMA32-753890202-3085). The revised Q&As are already published, the product-supplement Guidelines are finalised and awaiting translation, and the summary RTS has been submitted to the European Commission for adoption. None of those three is open for comment.

Are the updated disclosure Guidelines binding on issuers right now?

No. They are in draft form for consultation, and ESMA expects to publish the Final Report and updated Guidelines in Q2 2027. When finalised, ESMA Guidelines are not directly binding legislation, but Article 16(3) requires both competent authorities and financial market participants to make every effort to comply; competent authorities must notify ESMA whether they comply or intend to comply.

When do the Guidelines on product supplements start to apply?

Not from the 9 September 2026 Final Report publication itself. The Guidelines will apply when the translations into all official EU languages become available, per ESMA’s press release on the Final Report; confirm the exact trigger in ESMA32-753890202-3034 before implementation.

Is the updated summary key financial information RTS in force?

Not yet. ESMA published its Final Report on the update to the RTS concerning key financial information in the summary of a prospectus on 9 September 2026; Commission adoption of amended RTS would be required before those amendments become applicable law. Until the Commission adopts the updated RTS and it enters into force, the existing 2019/979 requirements for summary key financial information continue to apply.

What counts as a product supplement, and why does the test matter?

“Product supplement” is an informal abridged term for a supplement considered to introduce a new type of security not already described in a base prospectus. Article 23(4a) generally prohibits using a supplement to introduce a new type of security for which the necessary information was not included in the base prospectus, subject to the capital-requirements exception; Article 23(8) requires ESMA’s Guidelines to specify when a supplement is considered to introduce such a new type.

How do these Guidelines relate to the standardised prospectus format under the Listing Act?

They address different layers. The Level 1 standardised-format and sequence requirement in the Prospectus Regulation applied from 5 June 2026. The detailed amendments to Delegated Regulation (EU) 2019/980 were published as Commission Delegated Regulation (EU) 2026/1061 on 13 August 2026 and took effect on 16 August 2026. The disclosure Guidelines interpret how the disclosure content in the annexes of Commission Delegated Regulation (EU) 2019/980 should be completed. A shorter, standardised structure and leaner disclosure guidance are meant to work together, though they remain separate instruments with separate timing.

Related Articles

• ESAP First-Phase Data Collection: how the European Single Access Point will centralise prospectuses and regulated disclosure across the EU.
• ESMA APM Guidelines and IFRS 18 Interaction: where alternative performance measures meet the new income-statement structure in issuer disclosure.
• ESMA EU Green Bond External Reviewers Register: the issuer-reporting obligations that sit alongside a prospectus for labelled green bonds.
• Revised ESRS and Simplified CSRD Reporting: the parallel EU push to cut disclosure burden without losing decision-useful content.
• ESMA ESEF Taxonomy Update 2026: the machine-readable format that governs how issuers tag their annual financial reports.

Key Takeaways

• Responses to the disclosure Guidelines consultation (ESMA32-753890202-3085) are due by 9 November 2026; ESMA expects the Final Report and updated Guidelines in Q2 2027.
• Only the disclosure Guidelines are open for comment; the Q&As are already revised, the product-supplement Guidelines are at ESMA’s final-guidelines stage, and the summary RTS remain at ESMA Final Report/draft-RTS stage pending Commission adoption.
• ESMA published a Final Report on 9 September 2026 on updates to Commission Delegated Regulation (EU) 2019/979 on key financial information; Commission adoption of the amended RTS would be required before the changes become applicable law.
• The Guidelines on product supplements will apply when the translations into all official EU languages become available; confirm the exact trigger in ESMA Final Report ESMA32-753890202-3034.
• The package aligns the rulebook with the Listing Act (Regulation (EU) 2024/2809), whose core prospectus disclosure and format changes apply from 5 June 2026.
• Use ESMA’s overview of the Q&A changes as a change-log, and retire internal positions that cite a deleted or rewritten Q&A.
• Run a diff of house prospectus templates against the draft guidance, recording withdrawn guidance as carefully as new expectations.

Sources and References

• ESMA, “ESMA consults on disclosure requirements and updates guidelines and Q&As under the Prospectus Regulation”, 9 September 2026: esma.europa.eu
• Regulation (EU) 2017/1129 (Prospectus Regulation): eur-lex.europa.eu
• Regulation (EU) 2024/2809 (Listing Act, amending the Prospectus Regulation, MAR and MiFIR): eur-lex.europa.eu
• Commission Delegated Regulation (EU) 2019/980 (format, content, scrutiny and approval of the prospectus): eur-lex.europa.eu
• Commission Delegated Regulation (EU) 2026/1061 (amending Delegated Regulation (EU) 2019/980 as regards standardised format and sequence, streamlined content, scrutiny and approval): eur-lex.europa.eu
• Commission Delegated Regulation (EU) 2019/979 (RTS on key financial information in the summary and related matters): eur-lex.europa.eu
• Regulation (EU) No 1095/2010 (ESMA Regulation), Article 16 on guidelines and recommendations: eur-lex.europa.eu
• ESMA Guidelines on disclosure requirements under the Prospectus Regulation (Final Report ESMA31-62-1426, 15 July 2020) and ESMA prospectus page: esma.europa.eu
• ESMA Listing Act activity page: esma.europa.eu

Where to spend the autumn

The whole package reduces to one movable decision and three fixed ones. The movable decision is your response to the disclosure Guidelines consultation, due 9 November 2026, and the value in it lies in naming the specific annex items and the withdrawn guidance that affect how your issuers actually draft. The fixed decisions are how you absorb the revised Q&As, when the product-supplement Guidelines apply once translations into all official EU languages become available (Final Report ESMA32-753890202-3034), and how you plan summary tables around an RTS the Commission has not yet adopted. Put the comment letter first while it can still change the text, then work the other three tracks toward the Q2 2027 Final Report.

Disclaimer: The information on RegReportingDesk.com is for educational and informational purposes only. It does not constitute legal, regulatory, tax, or compliance advice. Always consult your compliance officer, legal counsel, or the relevant supervisory authority for guidance specific to your institution.